<DOC>
	<DOCNO>NCT01998893</DOCNO>
	<brief_summary>This study evaluate efficacy safety MabThera/Rituxan patient relapse low-grade centroblastic centrocytic non-Hodgkin ` lymphoma . Patients receive once-weekly intravenous MabThera/Rituxan 4 week ; respond patient treat second time case relapse ( defined progression complete partial response ) . The anticipated time study treatment &lt; 3 month .</brief_summary>
	<brief_title>A Study MabThera/Rituxan ( Rituximab ) Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>adult patient &gt; = 18 year age ; centrocytic centroblastic nonHodgkin ` lymphoma stage IIIIV ; relapse chemotherapy ( without interferon maintenance therapy ) . primary refractory lymphoma ; 3 relapse centroblastic centrocytic nonHodgkin ` lymphoma ; clinically significant cardiac disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>